Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Currentblue cross blue shield - south dakotaPolicy 07.01.60

07.01.60 Vagus Nerve Stimulation (VNS) and Vagal Nerve Blocking Therapy

Wellmark Blue Cross Blue Shield medical policy on implantable and transcutaneous vagus nerve stimulation and vagal nerve blocking therapy, describing indications considered medically necessary, investigational/unproven uses, rationale, evidence summaries, FDA device approvals, policy guidelines, and coding guidance. This part (1 of 6) includes description, evidence review summary, FDA approvals, coverage positions for implantable VNS, transcutaneous VNS, and vagal nerve blocking therapy, and policy metadata.

Policy Summary

Payerblue cross blue shield - south dakota

Policy07.01.60 Vagus Nerve Stimulation (VNS) and Vagal Nerve Blocking Therapy

Policy CodePolicy 07.01.60

Change TypeLiterature update / annual review (Apr 2025)

Effective DateNov 1, 2000

Next Review DateN/A

Key ActionProvider must document that seizures are medically refractory per Policy Guidelines.

SourceLink

POLICY UPDATE CHANGES

Policy updated with literature review through April 2025 and revisions noted April 2025.

April 2025 - Annual Review. Policy Revised.

April 2024 - Annual Review. Policy Revised.

1Medically Necessary Indication (implantable VNS)

3Investigational categories listed (tVNS, vBloc, other VNS uses)

1997-2017FDA device approval timeline (examples)

4Indications with RCT evidence discussed

≥50%Responder threshold used in many studies

969Total N for NYHA outcome in heart failure meta-analysis

494/301VNS vs No VNS patients in 5-year depression registry (Aaronson et al)

2RCTs for acute cluster headache treatment (ACT1, ACT2)

MixedOverall Efficacy

Few AEsSafety

Coverage Summary

This policy (Policy Number 07.01.60, effective 2000-11-01, most recently reviewed April 2025) addresses implantable and transcutaneous vagus nerve stimulation (VNS/tVNS/nVNS) and vagal nerve blocking (vBloc). Implantable VNS is considered medically necessary for individuals with medically refractory seizures who are not candidates for (or decline) epilepsy surgery when all policy criteria are met. Transcutaneous (non‑implantable) VNS devices (tVNS/nVNS) and vagal nerve blocking therapy (vBloc) are considered investigational for all indications (including obesity for vBloc and all indications for tVNS). Overall coverage stance is mixed, with implantable VNS supported for refractory partial‑onset (focal) seizures and other uses and technologies considered investigational as specified.

Key thresholds and facts

Medically Necessary IndicationImplantable VNS for medically refractory partial-onset seizures

Age threshold (FDA expanded indication)≥4 years

Investigational categoriestVNS (transcutaneous VNS); vagal nerve blocking therapy (vBloc); VNS for other conditions (depression, heart failure, stroke, obesity, autism, tinnitus, essential tremor, fibromyalgia, TBI, upper-limb post-stroke)

Policy Summary

Payerblue cross blue shield - south dakota

Policy07.01.60 Vagus Nerve Stimulation (VNS) and Vagal Nerve Blocking Therapy

Policy CodePolicy 07.01.60

Change TypeLiterature update / annual review (Apr 2025)

Effective DateNov 1, 2000

Next Review DateN/A

Key ActionProvider must document that seizures are medically refractory per Policy Guidelines.

SourceLink

On This Page

Medical Necessity and Coverage Criteria

Implantable Vagus Nerve Stimulation (VNS) - Medically Necessary

Covered when ALL of the following are met:

The patient has a diagnosis of epilepsy with partial-onset seizures or another seizure type for which VNS is an accepted adjunctive treatment and seizures are refractory to medical therapy.

There is documentation of failure, intolerance, or contraindication to an adequate trial of two or more antiseizure medications, used alone or in combination, that were appropriately selected for seizure type and tolerated.

The proposed therapy is delivered using an implantable VNS device by a clinician experienced in VNS management, and there is a plan for postoperative device programming and follow-up.

Replacement and Revisions - Medically Necessary

Covered when ALL of the following are met:

Replacement or revision of an implantable VNS generator or lead is medically necessary when there is device malfunction, battery depletion, or lead/device infection requiring removal or replacement.

There is documentation of current device interrogation demonstrating malfunction or battery depletion or clinical circumstances (e.g., device migration, infection) necessitating revision.

Replacement or revision solely for device upgrade when the existing device is functioning and no clinical indication exists is not covered.

Implantable VNS - Investigational

Not covered / Investigational when ANY of the following apply:

The use of implanted VNS for treatment-resistant depression, chronic heart failure, upper-limb impairment after stroke, or other neurologic, psychiatric, metabolic, or pain indications not listed as medically necessary in this policy.

The use of implanted VNS when the above medical-necessity criteria for refractory epilepsy are not met.

Implanted VNS for indications including but not limited to: essential tremor, headache (primary headache disorders other than specified coverage), fibromyalgia, tinnitus, autism spectrum disorder, traumatic brain injury, and other emerging neurologic or psychiatric indications without sufficient evidence of benefit.

Evidence Summary / Coverage Implication (acute migraine)

Evidence Summary / Coverage Implication (acute migraine):

Randomized trials of noninvasive/transcutaneous VNS (nVNS/tVNS) for acute treatment of episodic migraine have shown mixed results. One RCT in 248 patients did not meet the primary endpoint of being pain-free at 120 minutes without rescue medication (30% nVNS vs 20% sham; p=0.07) but showed secondary benefits for pain reduction from moderate/severe to mild/none and for being pain-free in at least 50% of attacks. Overall, evidence is insufficient to conclude a net health benefit for acute migraine treatment with nVNS.

Treatment durations in RCTs are short (weeks), quality of life and functional outcomes generally were not reported, and adverse events have been few and mild. Given inconsistent primary outcome results and limited duration, nVNS for acute migraine remains investigational for routine coverage.

Evidence Summary / Coverage Implication (preventive migraine)

Evidence Summary / Coverage Implication (preventive migraine):

Multiple randomized, sham-controlled trials have evaluated nVNS for prevention of chronic migraine. The PREMIUM phase 3 trial (n=341) and PREMIUM II (terminated early) did not demonstrate statistically significant superiority of nVNS over sham for primary prevention outcomes (≥50% reduction in migraine days, change in migraine days, or acute medication use). The EVENT feasibility study was not powered for efficacy.

Given negative or inconclusive results from adequately powered trials, the evidence does not support coverage of nVNS for prevention of chronic migraine as effective therapy.

Evidence Summary / Other indications (neurologic, psychiatric, metabolic)

Evidence Summary / Other indications (neurologic, psychiatric, metabolic):

Implanted VNS for treatment-resistant depression: RCTs and trials (including sham-controlled and dose-comparison studies) have not consistently shown short-term superiority on primary outcomes; nonrandomized and uncontrolled studies are limited by bias. Evidence is insufficient to establish net health benefit.

Implanted VNS for chronic heart failure: Some RCTs and uncontrolled studies report improvements in functional class, quality of life, 6-minute walk distance, and biomarkers, but inconsistencies and lack of robust control data limit confidence; evidence is insufficient.

Implanted VNS for post-stroke upper-limb impairment: Small RCTs show mixed results; pooled analyses suggest possible improvement in motor scores but longer-term outcomes and safety data are limited. Evidence is insufficient.

Other neurologic or metabolic indications (essential tremor, tinnitus, fibromyalgia, autism, TBI, obesity outside of vBloc): evidence consists largely of case series or nonexistent RCT data; insufficient to support coverage.

Evidence synthesis inclusion criteria (PICO and study selection)

Evidence synthesis inclusion criteria (PICO and study selection):

Population: Adults and children with the specific neurologic, psychiatric, or metabolic condition under study (e.g., refractory epilepsy, treatment-resistant depression, chronic migraine, chronic heart failure, post-stroke motor impairment).

Intervention: Implantable VNS systems or noninvasive/transcutaneous VNS devices (nVNS/tVNS) and vagal nerve blocking therapy (vBloc) as applicable.

Comparator: Sham stimulation, medical management, or no VNS intervention; randomized controlled trials prioritized. Uncontrolled observational studies and case series considered for safety and longer-term outcomes when RCTs absent.

Outcomes: Clinically meaningful endpoints including symptom reduction, seizure frequency, headache days, response/remission rates, functional outcomes, quality of life, and adverse events.

Study types: Randomized controlled trials, systematic reviews/meta-analyses, and controlled cohort studies prioritized; uncontrolled case series used only when higher-quality evidence is lacking. Trials with short double-blind periods, early termination, or high risk of bias were noted in interpretation.

tVNS / nVNS for other neurologic, psychiatric, metabolic disorders - evidence summary

tVNS / nVNS for other neurologic, psychiatric, metabolic disorders - evidence summary:

For cluster headache prevention and acute treatment, RCT data are limited and show inconsistent benefit; subgroup analyses suggest episodic cluster headache may respond better than chronic, but confirmatory trials focused on episodic disease are needed.

For other disorders evaluated with tVNS/nVNS (e.g., depression, tinnitus, fibromyalgia, autism), evidence is limited to small trials or case series with methodological limitations. Overall evidence across these indications is insufficient to determine net health benefit and does not support routine coverage.

Vagal nerve blocking therapy (vBloc) for obesity - evidence summary

Vagal nerve blocking therapy (vBloc) for obesity - evidence summary:

vBloc therapy aims to intermittently block intra-abdominal vagal signaling to reduce hunger and promote satiety. Randomized trials and longer-term follow-up have been conducted, but results demonstrate modest weight loss and mixed effects on metabolic outcomes when compared with control or sham procedures.

Available evidence does not robustly demonstrate clinically meaningful and durable weight loss or metabolic benefit sufficient to outweigh device risks and procedural complications; therefore, vBloc for obesity is considered investigational.

Study selection and interpretation caveats

Study selection and interpretation caveats:

Many RCTs have short double-blind treatment periods (often 2–12 weeks) limiting assessment of durability of benefit.

Some trials were terminated early (e.g., due to the COVID-19 pandemic) resulting in reduced statistical power and reliance on mITT analyses.

Several studies have relied on subgroup findings (episodic vs. chronic headache) or secondary endpoints when primary outcomes were not met; such findings require confirmation in prospective, adequately powered trials.

Uncontrolled observational studies and case series frequently report larger effects but are subject to selection bias, placebo effects, and lack of comparator groups; these limitations reduce confidence in efficacy conclusions.

Adverse events for nVNS/tVNS are generally mild and transient; implantable VNS and vBloc carry surgical risks including infection, device malfunction, and procedure-related complications — these safety considerations inform coverage determinations.

Investigational / Not Medically Necessary Indications

Transcutaneous Vagus Nerve Stimulation (tVNS) - Investigational

Transcutaneous (non-implantable) vagus nerve stimulation (tVNS) devices are considered investigational for all indications.

tVNS devices are investigational because evidence is insufficient to determine effects on net health outcomes

Vagal Nerve Blocking Therapy - Investigational

Vagal nerve blocking therapy is considered investigational for the treatment of obesity.

Vagal nerve blocking therapy for obesity is investigational because randomized trial primary efficacy endpoints were not met and evidence is insufficient to determine effects on net health outcomes

Evidence, Indication Summaries, and Rationale

Evidence-supported Indications and Strength of Evidence

Evidence summaries and conclusions by indication from randomized trials, observational studies, systematic reviews, and case series:

Treatment-Resistant Seizures

RCTs and meta-analyses report significant reduction in seizure frequency for patients with partial-onset (focal) seizures; uncontrolled studies report consistent ≥50% seizure-frequency reductions in adults and children.
Evidence limited by heterogeneity in comparators, follow-up length, medication data, mixed seizure etiologies, prior surgery history, and sponsor overlap.
Observational registry (VNS Therapy Patient Outcomes Registry) reports responder rates over time (0–4 mo: 50% responder; 4–12 mo: 55%; 12–24 mo: 55%; 24–48 mo: ≈60%) and seizure freedom rates (≈7–9%).
Registry participation ≈18% of implanted devices; data prospectively collected.

Treatment-Resistant Depression

Two RCTs (Rush et al 2005 sham-controlled; Aaronson et al 2013 dose-controlled) did not show consistent significant improvement in primary outcomes versus control; evidence insufficient to conclude VNS effectiveness for major depression.
Observational studies and registries report higher cumulative response and remission rates but are limited by nonrandomized design and baseline imbalances.
Common adverse events include voice alteration, dyspnea, pain; no clear increased risk of mania, hypomania, suicide, or worsening depression identified.
Patients with significant suicide risk were excluded from trials.

Chronic Heart Failure (reduced EF)

Systematic review and meta-analysis (Sant'Anna et al 2021) of 4 RCTs found significant improvements in NYHA class (OR 2.72), quality of life (MD -14.18 on MLwHFQ), 6-minute walk test (MD +55.46 m), and NT-proBNP (MD -144.25) versus sham; no mortality benefit.
GRADE reported high certainty for outcomes in the meta-analysis; RCTs N total=969 for NYHA outcome.
Uncontrolled studies/case series (ANTHEM-HF and ANTHEM-HFpEF) report improvements in LV ejection fraction, 6-minute walk distance, NYHA class and QoL, but lack of control limits conclusions.
Some long-term follow-up reports show sustained LVEF improvements at 12–36 months with high-intensity VNS.

Upper-Limb Impairment Due to Stroke

Three small RCTs (Dawson et al pilot and larger trial; Kimberley et al) and a systematic review (Ramos-Castaneda et al 2022) show implanted VNS plus rehabilitation improved upper-limb motor function (FMA-UE pooled MD = 2.78; individual larger RCT showed between-group FMA-UE difference 2.6 points, p=.0014) and higher clinically meaningful response rates in some trials.
One trial small and underpowered; surgical adverse events reported including vocal cord palsy, wound infection, dysphagia, dyspnea.

Other Neurologic Conditions

Evidence for other neurologic conditions (essential tremor, headache, fibromyalgia, tinnitus, traumatic brain injury, autism) is limited and investigational; current body of evidence in this document does not support definitive conclusions.
Trials and evidence selection criteria described but no robust positive RCT evidence summarized here.

Vagus nerve stimulation delivers electrical pulses to vagal afferent (and possibly efferent) pathways with diffuse central nervous system projections; stimulation is applied either via an implanted programmable pulse generator with leads around the left vagus nerve (implantable VNS) or noninvasively with handheld transcutaneous devices applied to the cervical/auricular regions (tVNS/nVNS). Several devices have received FDA clearance/approval, including the LivaNova VNS Therapy® system (initial approval 1997 with expanded pediatric seizure indication to age ≥4 in 2017) and gammaCore®/gammaCore‑2®/gammaCore‑Sapphire® (ElectroCore) for acute and preventive cluster and migraine indications (cleared 2017–2021); the Maestro® Rechargeable System (vBloc) received PMA approval in 2015 for specified BMI criteria but is reported as no longer marketed. Overall interpretation of the evidence is that implantable VNS is supported for medically refractory partial‑onset (focal) seizures based on RCTs, meta‑analyses, and registries, whereas evidence is insufficient to establish net health benefit for many other indications and for transcutaneous VNS and vagal nerve blocking therapy.

Evidence-based findings summarized by indication

Summaries of evidence and study-level findings for specific indications:

Upper-limb impairment due to stroke: Evidence consists of 3 small RCTs and a systematic review pooling their data; two RCTs compared VNS + rehabilitation vs rehabilitation alone (one positive, one negative); one RCT vs sham showed improved response but 3 serious surgical adverse events; systematic review found implanted VNS improved FMA-UE score vs control.

Other neurologic conditions (essential tremor, headache [non-cluster/migraine context], fibromyalgia, tinnitus, autism, traumatic brain injury): Evidence limited to small pilot studies or case series; no RCTs sufficient to draw conclusions for essential tremor, fibromyalgia, tinnitus, autism; planned RCT for TBI (Shi et al. 2013) but results not identified.

nVNS/tVNS for prevention of chronic cluster headache (PREVA trial): PREVA RCT (Gaul et al. 2016/2017) compared nVNS + SOC vs SOC; 4-week randomized period showed significant reduction in headache frequency and higher responder rate (≥50% reduction) and improved EQ-5D-3L; study was open-label/unblinded and short duration; adverse events few, mild, transient.

Study selection and interpretation are limited by methodological issues: many randomized trials are small or underpowered, there is imprecision in effect estimates, concerns about blinding or post‑randomization unblinding (especially in device trials), and reliance on post hoc analyses for longer‑term outcomes. These limitations (including high dropout rates in some tVNS trials, industry sponsorship overlap, and variable outcome definitions) affect confidence in treatment effects and generalizability.

Provider Actions, Documentation, and Prior Authorization

Documentation Required

Document medically refractory seizures

Document that seizures are medically refractory as defined in Policy Guidelines: seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels because of intolerable adverse effects.

Definition threshold: "Medically refractory seizures" = seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels because of intolerable adverse effects

Documentation Required

Document surgical candidacy

Document that the individual is not a candidate for epilepsy surgery or that they have declined surgical management prior to considering implantable VNS.

Explicit documentation that patient is not a surgical candidate or has refused surgery

Documentation Required

Responder and outcome measurement documentation

Document baseline seizure frequency or depression rating scale scores and subsequent follow-up measurements to assess treatment response (commonly a ≥50% reduction is used in trials). Also document prior medication trials and duration consistent with study criteria (e.g., prior failed medication trials as used in trials).

Baseline and follow-up seizure counts or depression scale scores
Responder threshold: ≥50% reduction from baseline
Record prior medication trials and durations (trial-level prior treatment failures)

Documentation Required

Patient selection and risk discussion

Document informed consent that the patient has been informed of expected benefits and known adverse events and surgical risks prior to implantation. Known adverse events to include voice alteration/voice change, dyspnea, pain, and potential surgical complications (e.g., vocal cord palsy, infection).

Document informed consent discussion
Document counseling on common adverse events: voice change/voice alteration, dyspnea, pain
Document surgical risks including vocal cord palsy, wound infection, dysphagia, and device-related surgical complications

Prior Authorization

Potential requirement for medical necessity review

Prior authorization or medical necessity review may be appropriate for implanted VNS, transcutaneous VNS (tVNS/nVNS), and vBloc therapy to confirm eligibility and that prior conservative therapies were attempted and failed. Ensure documentation of prior conservative therapies and treatment attempts as part of the review.

See device therapy considerations for obesity: ensure patients have attempted conservative weight-loss therapies before vBloc (Maestro) implantation
Consider prior authorization to require documentation of prior standard therapies and responses

Documentation Required

Registry/post-marketing follow-up expectation

Document participation in registries or post-market surveillance when applicable and note evidence limitations when counseling patients. When discussing treatment options, document trial-level evidence limitations (small sample sizes, imprecision, limited blinded follow-up, post hoc analyses) and the uncertainty of benefit for many indications.

Registry expectation: VNS Therapy Patient Outcomes Registry contains prospective data and has contributed long-term outcomes (registry responder rates over time noted)
Document evidence limitations and indication-specific trial limitations when counseling patients (e.g., small RCTs, short double-blind periods, methodological limitations, post hoc analyses)

Definitions and Key Thresholds

Key definitions and numeric thresholds used in this policy.

Definitions and thresholds

Medically refractory seizures (definition)Seizures that occur despite therapeutic levels of antiepileptic drugs or cannot be treated with therapeutic levels because of intolerable adverse effects

Responder (general)Subject achieving ≥50% reduction from baseline in seizure frequency or depression rating scale score

Age threshold (seizures, FDA)≥4 years (expanded indication for adjunctive therapy for partial-onset seizures)

Maestro (vBloc) BMI eligibilityAdults ≥18 years with BMI 40–45 kg/m2 or BMI 35–39.9 kg/m2 plus ≥1 obesity-related condition and failed ≥1 supervised weight management program within past 5 years

ReCharge primary efficacy margin (vBloc)>10% difference in percent excess weight loss (EWL) between groups at 12 months

6-minute walk test (heart failure meta-analysis)Mean difference +55.46 meters

Follow-up durations of interest for depressionShort-term: 2–6 months; Long-term: 1–2 years

OpenPayer

07.01.60 Vagus Nerve Stimulation (VNS) and Vagal Nerve Blocking Therapy

Coverage Summary

Medical Necessity and Coverage Criteria

Investigational / Not Medically Necessary Indications

Evidence, Indication Summaries, and Rationale

Coding Guidance

Provider Actions, Documentation, and Prior Authorization

Definitions and Key Thresholds

Medicare Determinations

Revision History